The goal of this study is to develop a safe, well tolerated, and highly efficacious
azithromycin combination treatment for uncomplicated falciparum malaria. Azithromycin is a
drug that has shown potential for malaria treatment. It will be combined with other malaria
drugs currently approved for treatment in Thailand. About 120 people, ages 20-65, will be
enrolled in Thailand. Participants will have severe cases of malaria and they will be
hospitalized 28 days for treatment.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)